Exploring subtype selectivity and metabolic stability of a novel series of ligands for the benzodiazepine binding site of the GABAA receptor

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 5, 2011, Pages 1523-1526

  Hintermann, Samuel ^a   Hurth, Konstanze ^a   Nozulak, Joachim ^a   Tintelnot Blomley, Marina ^a   Aichholz, Reiner ^a   Blanz, Joachim ^a   Kaupmann, Klemens ^a   Mosbacher, Johannes ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

GABAA ligands; Metabolic stability; Subtype selectivity

Indexed keywords

2 (4 CHLOROPHENYL) 5H PYRAZOLO[4,3 C]QUINOLIN 3 ONE; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; BENZODIAZEPINE; LIGAND; MIDAZOLAM; OXYGEN; PYRAZOLONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; CHEMICAL BINDING; CONTROLLED STUDY; DERIVATIZATION; DRUG CLEARANCE; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STABILITY; IN VITRO STUDY; IN VIVO STUDY; METABOLIC REGULATION; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

BENZODIAZEPINES; BINDING SITES; DRUG STABILITY; GABA-A RECEPTOR AGONISTS; INHIBITORY CONCENTRATION 50; LIGANDS; MOLECULAR STRUCTURE; PYRAZOLES; RECEPTORS, GABA-A; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79951722446     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.12.107     Document Type: Article

References (12)

1. C.B. Nemeroff J. Clin. Psychiatry 64 2003 3
2. U. Rudolph, F. Crestani, D. Benke, I. Brunig, J.A. Benson, J.-M. Fritschy, J.R. Martin, H. Bluethmann, and H. Mohler Nature 401 1999 796
3. K. Low, F. Crestani, R. Keist, D. Benke, I. Beunig, J.A. Benson, J.-M. Fritschy, T. Ruicke, H. Bluethmann, H. Mohler, and U. Rudolph Science 290 2000 131
4. R.M. McKernan, T.W. Rosahl, D.S. Reynolds, C. Sur, K.A. Wafford, J.R. Atack, S. Farrar, J. Myers, G. Cook, P. Ferris, L. Garrett, L. Bristow, G. Marshall, A. Macaulay, N. Brown, O. Howell, K.W. Moore, R.W. Carling, L.J. Street, J.L. Castro, C.I. Ragan, G.R. Dawson, and P.J. Whiting Nat. Neurosci. 3 2000 587
5. A. Mitchinson, J.R. Atack, P. Blurton, R.W. Carling, J.L. Castro, K.S. Curley, M.G.N. Russell, G. Marshall, R.M. McKernan, K.W. Moore, R. Narquizian, A. Smith, L.J. Street, S.-A. Thompson, and K. Wafford Bioorg. Med. Chem. Lett. 14 2004 3441
6. Y. Hirschberg, R.L. Oberle, M. Ortiz, H. Lau, and M. Markowska J. Pharmacokinet. Biopharm. 23 1995 11
7. M. Williams, D.A. Bennett, P.S. Loo, A.F. Braunwalder, C.L. Amrick, D.E. Wilson, T.N. Thompson, M. Schmutz, N. Yokoyoma, and J.W.F. Wasley J. Pharmacol. Exp. Ther. 248 1989 89
8. C. Joesch, E. Guevarra, S.P. Parel, A. Bergner, P. Zbinden, D. Konrad, and H. Albrecht J. Biomol. Screen 13 2008 218
9. 3H-Ro-15-1788; NEN PerkinElmer) were incubated for 45 min at RT in 96 wells and subsequently filtered using 96-Unifilter GF/C (Packard) or MAHFC1H60 (Millipore) plates. Non-specific binding was determined in the presence of 1 μM flumazenil. Data were analyzed by non-linear curve fitting using GraphPad Prism 4 software (triplicate determination ± SEM).
10. Yokoyama, N. Patent application EP 22078.
11. Yokoyama, N. Patent application US4647566.
12. 2O in the mobile phase).